Leukemias pp 267-275 | Cite as

Chronic Myeloproliferative Syndromes: Initial Findings, Evolution, and Prognosis in 489 Patients

  • H. Heimpel
  • U. Haug
  • R. Seidler
  • B. Anger
Conference paper


Chronic myeloproliferative syndromes (c-MPS) comprise a group of clonal diseases of hematopoietic stem cells. Conventionally, they are subclassified into polycythemia vera (PV), chronic myeloid leukemia (CML), essential thrombocythemia (ET), and idiopathic myelofibrosisis (IMF). This contribution reports data collected over a 20-year period in one institution and then retrospectively analyzed. Both diagnostic procedures and treatment modalities had been prospectively defined as standard routines.


Polycythemia Vera Essential Thrombocythemia Chronic Myeloid Leukemia Patient Polycythemia Vera Patient Chronic Myeloproliferative Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L (1976) Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 295:913–916PubMedCrossRefGoogle Scholar
  2. 2.
    Anger B, Haug U, Seidler R, Heimpel H (1989) Polycythemia vera. A clinical study of 141 patients. Blut 59:493–500PubMedCrossRefGoogle Scholar
  3. 3.
    Anger B, Janssen JWG, Schrezenmeier H, Hehlmann R, Heimpel H, Bartram CR (1990) Clonal analysis of chronic myeloproliferative disorders using x-linked DNA polymorphism. Leukemia 4:258–61PubMedGoogle Scholar
  4. 4.
    Anger B, Schmeiser T, Heimpel H, Robertson J, Sokal JE, Ganser A, Carbonell F (1990) Evaluation von 196 Patienten mit chronischer myeloischer Leukämie anhand eines Standard-Prognose-Modells. Onkologie 13:109–114PubMedCrossRefGoogle Scholar
  5. 5.
    Anger B, Seidler R, Haug U, Popp C, Heimpel H (1987) Agnogenic myeloid metaplasia with myelofibrosis (AMM/MF): clinical course and prognosis of 103 patients. Blut 55:283–280Google Scholar
  6. 6.
    Anger B, Seidler R, Haug U, Popp C, Heimpel H (1990) Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 75:228–234PubMedGoogle Scholar
  7. 7.
    Anger B, Seifried E, Scheppach I, Heimpel H (1989) Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67:818–825PubMedCrossRefGoogle Scholar
  8. 8.
    Bendix-Hansen K, Bergmann OJ (1985) Evaluation of neutrophil alkaline phosphatase (NAP) activity in untreated myeloproliferative syndromes and in leukaemoid reactions. Scand J Haematol 35:219–224PubMedCrossRefGoogle Scholar
  9. 9.
    Bouroncle BA, Doan CA (1962) Myelofibrosis: clinical, hematological and pathologic study of 110 patients. Am J Med 243:697–715CrossRefGoogle Scholar
  10. 10.
    Buschle M, Janssen JWG, Drexler H, Lyons J, Anger B, Bartram CR (1988) Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2:658–660PubMedGoogle Scholar
  11. 11.
    Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Sem Hematol 23:144–155Google Scholar
  12. 12.
    Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queißer U, Vaupel H, Walther F, Hossfeld DK, Zimmermann R, Heiss F, Mende S, Tigges FJ, Kleeberg UR, Pralle H, Kayser W, Tichelli A, Faulhaber JD, Räth U, Schubert H, Bross K, Schlag R, Schmid L, Weißenfels I, Heinze B, Georgii A, Queißer W, Heimpel H (1988) Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56:87–91PubMedCrossRefGoogle Scholar
  13. 13.
    Janssen JWG, Anger BR, Drexler HG, Bartram CR, Heimpel H (1990) Essential thrombocythemia in two sisters originating from different stem cell levels. Blood 75:1633–1636PubMedGoogle Scholar
  14. 14.
    Schafer AJ (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1–12PubMedGoogle Scholar
  15. 15.
    Schmeiser T, Arnold R, Wiesneth M, Hertenstein B, Bunjes D, Anger B, Heit W, Heimpel H (1988) Knochenmarktransplantation als Therapie der chronisch-myeloischen Leukämie. Dtsch Med Wochenschr 113:6–10PubMedCrossRefGoogle Scholar
  16. 16.
    Singal U, Prasad AS, Halton DM, Bishop C (1983) Essential thrombocythemia: a clonal disorder of hematopoietic stem cell. Am J Hematol 14:193–196PubMedCrossRefGoogle Scholar
  17. 17.
    Thiele J, Simon K-G, Fischer R (1988) Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteo-myelofibrosis — evolution of histopathological lesions and clinical course in 40 patients. Pathol Res Pract 183:434–445PubMedCrossRefGoogle Scholar
  18. 18.
    Ward HP, Block MH (1971) The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine 50:357–420PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • H. Heimpel
    • 1
  • U. Haug
  • R. Seidler
  • B. Anger
  1. 1.Medizinische Klink und Poliklinik der Universität UlmAbteilung Innere Medizin IIIUlmGermany

Personalised recommendations